Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.64)
# 812
Out of 4,979 analysts
98
Total ratings
51.14%
Success rate
6.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Initiates: Buy | $6 | $1.49 | +302.68% | 1 | Sep 9, 2025 | |
| SLNO Soleno Therapeutics | Reiterates: Buy | $106 | $72.30 | +46.61% | 5 | Aug 27, 2025 | |
| PASG Passage Bio | Maintains: Buy | $40 → $10 | $6.92 | +44.51% | 3 | Aug 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $101 → $106 | $56.38 | +88.01% | 4 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $558 → $546 | $395.25 | +38.14% | 8 | Aug 6, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $64 | $31.51 | +103.11% | 3 | Jun 20, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $50 | $13.30 | +275.94% | 5 | Jun 18, 2025 | |
| QURE uniQure | Reiterates: Buy | $28 | $17.43 | +60.64% | 6 | May 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $11.84 | +280.07% | 2 | May 12, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $145.20 | +30.17% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $19.94 | +175.83% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $98 | $17.60 | +456.82% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $64 | $61.00 | +4.92% | 5 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $14.97 | +26.92% | 2 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $18.03 | +55.30% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $7.95 | - | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.89 | +362.72% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $13.83 | +22.92% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.98 | +87.97% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $54.10 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.97 | +282.29% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.26 | +416.43% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $25.09 | +19.57% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.14 | +2,443.86% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $455.03 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $3.24 | +764.20% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.58 | +163.85% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $33.55 | +266.62% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $15.19 | +255.50% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.15 | +5,117.39% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $36.41 | - | 3 | Jun 26, 2017 |
PepGen
Sep 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.49
Upside: +302.68%
Soleno Therapeutics
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $72.30
Upside: +46.61%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $6.92
Upside: +44.51%
BioMarin Pharmaceutical
Aug 6, 2025
Maintains: Buy
Price Target: $101 → $106
Current: $56.38
Upside: +88.01%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $395.25
Upside: +38.14%
Ultragenyx Pharmaceutical
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $31.51
Upside: +103.11%
Dyne Therapeutics
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $13.30
Upside: +275.94%
uniQure
May 12, 2025
Reiterates: Buy
Price Target: $28
Current: $17.43
Upside: +60.64%
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $11.84
Upside: +280.07%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $145.20
Upside: +30.17%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $19.94
Upside: +175.83%
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $17.60
Upside: +456.82%
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $61.00
Upside: +4.92%
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $14.97
Upside: +26.92%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $18.03
Upside: +55.30%
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $7.95
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.89
Upside: +362.72%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $13.83
Upside: +22.92%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.98
Upside: +87.97%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $54.10
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.97
Upside: +282.29%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $4.26
Upside: +416.43%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $25.09
Upside: +19.57%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.14
Upside: +2,443.86%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $455.03
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $3.24
Upside: +764.20%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.58
Upside: +163.85%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $33.55
Upside: +266.62%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $15.19
Upside: +255.50%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.15
Upside: +5,117.39%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $36.41
Upside: -